mRNA Drug Impurity Profiling Questions
Please fill out the form below to request a quote and/or apply to the Early Access Program and a Rockland representative will reach out for next steps.
*Required field(s)
Full Name*
Email*
Company Name*
Country
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Cote D'Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
ARGENTINA
ITALY
CANADA
SOUTH KOREA
NETHERLANDS
AUSTRALIA
JAPAN
TURKEY
CHINA
GERMANY
FRANCE
UNITED KINGDOM
ISRAEL
FINLAND
SINGAPORE
MALTA
SWITZERLAND
INDIA
NEW ZEALAND
USA
Which product(s) are you interested in purchasing?
T7 RNA polymerase antibody
T4 RNA ligase antibody
What other impurities and vaccine by-product targets are you interested in detecting?
VCE Capping Enzyme
2’-O-methyltransferase
PolyA Polymerase
Pyrophosphatase
Unincorporated dNTPs
Residual DNA Template
dsRNA
uncapped mRNA
E. Coli host proteins
Nucleases (Please specify in Additional Details Section)
BSA
LNP
PEG
What type of RNA or Nucleic Acid vaccines do you work with?
mRNA vaccines - Non-amplifying
mRNA vaccines - Self-amplifying
Circular (circ) RNA vaccines
DNA vaccines
Other (Please specify in Additional Details Section)
In what phase(s) of drug development would the panel(s) be used?
Discovery
Pre-clinical
Clinical
What immunoassay(s) would be used with our panel(s)?
ELISA - ADA assays
ELISA - Immunogenicity studies
ELISA - PK studies
ELISA - PD studies
ELISA - Other
IF
IHC
Flow Cytometry
Additional details or questions:
SUBMIT